Navigation Links
Xlumena Receives CE Mark for Revolutionary AXIOS™ Stent and Delivery System
Date:5/5/2011

MOUNTAIN VIEW, Calif., May 5, 2011 /PRNewswire/ -- Xlumena, Inc., a privately-held provider of innovative technology for the interventional endoscopist and endoscopic surgeon, announced today that it has received CE Mark approval for its revolutionary AXIOS™ Stent and Delivery System (AXIOS). The AXIOS is the first stent designed for endoscopic ultrasound-guided translumenal therapy and is indicated for drainage of pancreatic pseudocysts. Having achieved this important milestone, Xlumena will begin a targeted commercial launch of the AXIOS in select European markets.  

"The AXIOS Stent opens up a frontier of new treatments in and around the gastrointestinal tract.  Not only does the AXIOS Stent create a large, secure drainage pathway – equivalent to a surgical anastomosis – it also provides an access port to pass the endoscope into the duct or lumen cavity for targeted therapy.  This technology has the potential to expand the role of endoscopy in treating a variety of disorders of the pancreatic and biliary system," stated Kenneth Binmoeller, MD, Director of Interventional Endoscopy Services at California Pacific Medical Center in San Francisco, California.

Unlike tubular stents used for bile and pancreatic duct drainage, the AXIOS Stent is designed to hold two lumens in apposition for translumenal drainage.  The bilateral anchors of the AXIOS Stent prevent movement and migration and the large-diameter Stent lumen ensures drainage.   The AXIOS is fully covered to prevent leakage across the stent and tissue ingrowth and facilitate removal.  The AXIOS Stent comes pre-loaded in a specially-designed Delivery System and is easily deployed by a single operator.

"AXIOS leverages the expertise and vision of the interventional endoscopy community. It represents a new frontier in endoscopic therapy that uses ultrasound to guide intervention outside of the gastrointestinal tract. This avoids more invasive treatments such as surgery," commented Michael Allen, Xlumena's President and CEO.  "Xlumena is committed to advancing endoscopic treatment options through the development of safe, efficient and easy to use technologies."

About the AXIOS Stent and Delivery System

The AXIOS Stent is fully-covered, self-expandable and available in multiple lumen diameters (15mm, 10mm, 8mm and 6mm) and lengths (10mm, 6mm and 4mm) to ensure a custom fit. The Delivery System is ergonomic and allows the interventional endoscopist to control and precisely deliver the AXIOS to the intended target using a single hand. To view an animation of the AXIOS Stent and Delivery System, visit http://www.vimeo.com/xlumena/axios

About Xlumena

Xlumena is the leader in the development of image-guided therapeutic endoscopy products, specializing in advanced implants and devices for a new, rapidly growing field of medicine. Collaborating with top physicians in the field, Xlumena focuses on technologies that advance therapy to the next level. These innovations may enable numerous translumenal therapeutic procedures, helping transform complex surgeries into outpatient events.

To view an animation of Xlumena's first product, the NAVIX Access Device (FDA cleared), visit http://www.vimeo.com/xlumena/navix

Contact: Witney McKiernan  650.961.9900


'/>"/>
SOURCE Xlumena, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Clears Xlumenas NAVIX(TM) Access Device
2. Xlumena, Inc. Closes $7M Series B Venture Financing Round
3. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
7. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
8. CryoCor Receives FDA Approval for Right Atrial Flutter
9. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
10. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
11. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
Breaking Medicine Technology:
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
Breaking Medicine News(10 mins):